The results of this study may allow us to develop strategies to limit radiation damage and improve patients’ QoL, as well as predictive or prognostic models of bladder toxicity from irradiation radiotherapy in patients with prostate cancer combining clinical parameters, individual patient characteristics, and M-CSF levels in urine and blood. This evidence concerns the gene CSF1 and prostate carcinoma.